Search Result

Results for "

gallbladder

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (3) Biochemical Assay Reagents (1) Cholecystokinin Receptor (11) Endogenous Metabolite (4) Eukaryotic Initiation Factor (eIF) (1) G protein-coupled Bile Acid Receptor 1 (1) Histamine Receptor (1) HIV (3) Liposome (3) mTOR (1) Neurokinin Receptor (1) PI3K (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (7) Endocrinology (4) Infection (5) Inflammation/Immunology (3) Metabolic Disease (12) Neurological Disease (1)
Oligonucleotides:	Cholesterol (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W587430

Glycolithocholic acid 3-sulfate disodium Glycolithocholate sulfate disodium; Sulfolithocholylglycine disodium; SLCG disodium	HIV	Infection
Glycolithocholic acid 3-sulfate (disodium) inhibits replication of HIV-1 in vitro. Glycolithocholic acid 3-sulfate (disodium) can be used for the research of HIV infection and gallbladder disease .

HY-P2636

Cholecystokinin Precursor (24-32) (rat) Prepro CCK Fragment V-9-M	Histamine Receptor	Metabolic Disease
Cholecystokinin Precursor (24-32) (rat) is a cholecystokinin precursor that can be expressed in the heart, lungs, and kidneys as well as in the gastrointestinal tract and brain. Cholecystokinin is a brain-gut peptide that stimulates gallbladder contraction and pancreatic exocrine secretion and also acts as a neurotransmitter .

HY-113074

Glycolithocholic acid 3-sulfate Glycolithocholate sulfate; Sulfolithocholylglycine; SLCG	HIV Endogenous Metabolite	Infection Inflammation/Immunology
Glycolithocholic acid 3-sulfate (SLCG) is a cholic acid derivative and a metabolite of glycolithocholic acid. Glycolithocholic acid 3-sulfate inhibits replication of HIV-1 in vitro. Glycolithocholic acid 3-sulfate can be used for the research of HIV infection and gallbladder disease .

HY-P0093

Sincalide 3 Publications Verification Cholecystokinin octapeptide; CCK-8; SQ19844	Cholecystokinin Receptor Apoptosis PI3K Akt	Infection Cancer
Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK .

HY-P0093A

Sincalide ammonium 3 Publications Verification Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium	Cholecystokinin Receptor Apoptosis PI3K Akt	Infection Cancer
Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK .

HY-A0190

Ceruletide Maximum Cited Publications 97 Publications Verification Caerulein; Cerulein; FI-6934	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-P3652

Cholecystokinin-33 (swine)	Cholecystokinin Receptor	Metabolic Disease
Cholecystokinin-33 (swine) is a cholecystokinin (CCK) fragment. Cholecystokinin-33 (swine) can reduce food intake and gallbladder contraction .

HY-122998

Iodoalphionic acid Priodax; Pheniodol	Biochemical Assay Reagents	Others
Iodoalphionic acid (Priodax) is a contrast agent that can be used for gallbladder examination .

HY-146453

TGR5 Receptor Agonist 3	G protein-coupled Bile Acid Receptor 1	Metabolic Disease
TGR5 Receptor Agonist 3 (Compound 19) is a soft-agent G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonist with reduced gallbladder-filling effects (favorable gallbladder safety), with EC50s of 16.4 and 209 nM for hTGR5 and mTGR5, respectively.

HY-158722

Caerulein acetate	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Caerulein acetate is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide acetate is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-P10268

Neuropeptide K (human, porcine, rat)	Neurokinin Receptor	Cardiovascular Disease Neurological Disease
Neuropeptide K, human, porcine, rat exhibits bioactivity in gallbladder contraction, protein extravasation, hypotension and brcnchial smooth muscle spasm. Neuropeptide K, human, porcine, rat is concentrated in brain and acts as tachykinin neuromessenger .

HY-118311

(Z)-W 3699 (Z)-Probilin; (Z)-Secrebil; (Z)-Piprozolin	Others	Metabolic Disease
(Z)-W 3699 is a potential choleretic. (Z)-W 3699 can increase the solubility of cholesterol in the gallbladder by altering the secretion of micellar bile acids. (Z)-W 3699 can prevent the formation of cholesterol-containing gallstones in dogs.

HY-A0190R

Ceruletide (Standard)	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Ceruletide (Standard) is the analytical standard of Ceruletide. This product is intended for research and analytical applications. Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-W339757

Dioctanoylphosphatidic acid sodium	mTOR Endogenous Metabolite	Cancer
Dioctanoylphosphatidic acid sodium functions as a modulator of phagocyte respiratory burst, acts as a precursor to diacylglycerol and lysophosphatidic acid, and influences the phosphorylation of the mammalian target of rapamycin (mTOR) while enhancing the viability of gallbladder carcinoma cells treated with histone deacetylase inhibitors (HDACIs); it is derived from glycerophospholipid through the action of phospholipase D.

HY-118546

JNJ-17156516	Cholecystokinin Receptor	Inflammation/Immunology
JNJ-17156516 is an orally active, potent, and selective cholecystokinin (CCK)1-receptor antagonist .

HY-106301

Devazepide 4 Publications Verification L-364,718; MK-329	Cholecystokinin Receptor	Metabolic Disease
Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC₅₀s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders .

HY-172281

DSPE-PEG1000-CCK8	Liposome	Cardiovascular Disease
DSPE-PEG1000-CCK8 is a PEG compound which composed of DSPE and a Cholecystokinin-8 (CCK8). Cholecystokinin-8 has the activity of peptide regulating gallbladder contraction and digestive system function. DSPE-PEG1000-CCK8 can be used for drug delivery .

HY-172281B

DSPE-PEG5000-CCK8	Liposome	Cardiovascular Disease
DSPE-PEG5000-CCK8 is a PEG compound which composed of DSPE and a Cholecystokinin-8 (CCK8). Cholecystokinin-8 has the activity of peptide regulating gallbladder contraction and digestive system function. DSPE-PEG5000-CCK8 can be used for drug delivery .

HY-172281A

DSPE-PEG2000-CCK8	Liposome	Cardiovascular Disease
DSPE-PEG2000-CCK8 is a PEG compound which composed of DSPE and a Cholecystokinin-8 (CCK8). Cholecystokinin-8 has the activity of peptide regulating gallbladder contraction and digestive system function. DSPE-PEG2000-CCK8 can be used for drug delivery .

HY-121799A

Taurohyocholic acid sodium salt THCA sodium salt	Endogenous Metabolite	Others
Taurohyocholic acid (THCA) sodium salt is a taurine-conjugated hyocholic acid. Taurohyocholic acid sodium salt is predictor of the efficacy of tyrosine kinase inhibitors combined withPD-1 inhibitors in hepatocellular carcinoma (HCC) .

HY-106301R

Devazepide (Standard)	Cholecystokinin Receptor	Metabolic Disease
Devazepide (Standard) is the analytical standard of Devazepide. This product is intended for research and analytical applications. Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC₅₀s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders .

HY-113074R

Glycolithocholic acid 3-sulfate (Standard)	HIV Endogenous Metabolite	Infection Inflammation/Immunology
Propyzamide (Standard) is the analytical standard of Propyzamide. This product is intended for research and analytical applications. Propyzamide is a anti-microtubule herbicide .

HY-136453

CR-1-31-B 5+ Cited Publications	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells .

HY-101764

Lintitript SR 27897	Cholecystokinin Receptor	Metabolic Disease
Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC₅₀ of 6 nM and a K_i of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC₅₀ value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin .

HY-19261

T-0632	Cholecystokinin Receptor	Metabolic Disease
T-0632 is a CCK A receptor antagonist that exhibits significant pharmacological properties in in vitro studies. T-0632 competitively inhibits the binding of [125I]CCK-8 to rat pancreatic CCK A receptors with a K_i value of 0.24 nM, which is significantly lower than the K_i value for guinea pig CCK B receptors. T-0632 has higher selectivity in inhibiting CCK-8-stimulated pancreatic enzyme release, with an IC_50 value of 5.0 nM, which is more advantageous than L-364,718 and loxiglumide. In rabbit gallbladder smooth muscle, the antagonistic effects of T-0632 and loxiglumide are reversible, while L-364,718 shows a persistent inhibitory effect. These results indicate that T-0632 is a highly potent, reversible and more selective CCK A receptor antagonist.

Cat. No.	Product Name

HY-L208

Bile Acids Library	58 compounds
Bile acids are a class of amphiphilic molecules derived from the metabolic breakdown of cholesterol, primarily synthesized in the liver, and play a crucial role in the intestines. Based on their structural characteristics, bile acids are mainly divided into two categories: free bile acids (including Cholic acid, Deoxycholic acid, Chenodeoxycholic acid) and conjugated bile acids (including Glycocholic acid, Glycochenodeoxycholic acid, Taurocholic acid, etc.). Bile acids play a significant role in the pathophysiological research of liver and gastrointestinal diseases and are closely associated with the occurrence of metabolic diseases such as obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Bile acids maintain metabolic balance within the body by regulating sugar metabolism, lipid metabolism, and amino acid metabolism, and they influence the activity of metabolism-related enzymes and transporters. In addition, Bile acids can also be used to construct a bile acid metabolism research platform, which helps to delve into the metabolic pathways and dynamic changes of bile acids in living organisms and aids in identifying new biomarkers for certain diseases. MCE included 58 bile acids, including Cholic acid, Deoxycholic acid, Glycocholic acid, etc., which are effective tools for the study of liver and gallbladder diseases.

Bile Acids Library

58 compounds

Bile acids are a class of amphiphilic molecules derived from the metabolic breakdown of cholesterol, primarily synthesized in the liver, and play a crucial role in the intestines. Based on their structural characteristics, bile acids are mainly divided into two categories: free bile acids (including Cholic acid, Deoxycholic acid, Chenodeoxycholic acid) and conjugated bile acids (including Glycocholic acid, Glycochenodeoxycholic acid, Taurocholic acid, etc.). Bile acids play a significant role in the pathophysiological research of liver and gastrointestinal diseases and are closely associated with the occurrence of metabolic diseases such as obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Bile acids maintain metabolic balance within the body by regulating sugar metabolism, lipid metabolism, and amino acid metabolism, and they influence the activity of metabolism-related enzymes and transporters. In addition, Bile acids can also be used to construct a bile acid metabolism research platform, which helps to delve into the metabolic pathways and dynamic changes of bile acids in living organisms and aids in identifying new biomarkers for certain diseases.

MCE included 58 bile acids, including Cholic acid, Deoxycholic acid, Glycocholic acid, etc., which are effective tools for the study of liver and gallbladder diseases.

Cat. No.	Product Name	Type